New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 16, 2017 – Boehringer Ingelheim announced the FDA approval of Spiriva Respimat (tiotropium bromide) for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.
Download PDF
Return to publications
